News
Engineers develop bio-machine nose that can “sniff” and classify odors
Engineers from Brown University in Rhode Island have invented a small, low-cost sensor device which is able to classify odors using input from a mimicked “sniffing” action. It’s called TruffleBot, and it’s here to raise the bar on electronic “noses”. It also works with Raspberry Pi, an inexpensive mini-computer popular with electronics hobbyists, students, and others in the “maker” crowd.
Generally, an electronic nose is a device comprising several chemical sensors whose results are fed through a pattern-recognition system to identify odors. In traditional devices, the chemical responses alone are used for classification. The engineers behind this invention, however, decided to incorporate non-chemical data to account for the mechanics of the smell process used in nature for a better result. Their experiment proved successful with an approximate 95-98% rate of accuracy in identification compared to about 80-90% accuracy with the chemical sensors alone.
According to the inventors’ published paper, the guiding knowledge that made TruffleBot so useful in odor detection was this: Different smells have different impacts on the air around them, and measuring the variations enables more accurate identification. Did you know that beer odor decreases air pressure and increases temperature? The changes are slight, but TruffleBot can sense them.
This is where the “sniffing” comes in. The device uses air pumped through four obstructed pathways before sending it through chemical and non-chemical sensors. Odors impact the air surrounding them, and the movement of the air through obstacles (“sniffing”) enables the odors’ impact to be more accurately measured.
A chart detailing how TruffleBot processes odors. | Credit: Brown University
So, where exactly would one need an electronic nose? Everywhere. Devices with the chemical sensing ability are being used in agriculture, military, and commercial applications to identify all sorts environmental data. Essentially, electronic noses are useful in any industrial application that has odor involved.
Nasal Marketing
Did you know that it’s possible to trademark a smell in the United States? It’s not easy to accomplish given the somewhat difficult requirements to meet, but a few such things exist. The fact that Play-Doh, a product whose smell is probably one of its most distinct features, was granted a trademark for the scent only this year is testament to the difficulty of obtaining such a mark. However, the fact that some companies have found enough incentive to make sure only their company can give your nose a particular chemical experience tells a lot about that sense’s importance from a marketing perspective.
On one hand, utilizing smell in marketing might seem a little manipulative. After all, creating an air freshener that reminds someone of a beloved, deceased relative on purpose might not seem like a particularly ethical way to target their money. On the other hand (or bigger picture), however, the motivation for marketers to use scent as a tool involves a sort of “chicken or the egg” question.
To summarize part of an article in the journal Sensors on the role scent plays in society and commerce, the aroma of products has a direct impact on their appeal to customers and thus, the success of the product. In fact, a change in a product’s formula that impacts its smell can, and often has had, devastating sales results. In other words, it’s not enough for a company to create a good product; it has to be a good smelling product.
Hacking the Human Nose
It’s probably no surprise that the commercial industry has categorized consumer preferences when it comes to smells. As the first sense fully developed after birth, our noses link us to things like memories, emotions, and chemical communication (think pheromones). Is it any wonder, then, why businesses might be interested in the functionality of the organ that is doing the receiving?
Turns out, there’s an enormous amount of science behind “hacking” a nose. Identifying smells is more than just categorizing chemical mixtures as “floral” or “masculine”. The multitude of chemical combinations available generates such a vast amount of data that scientists have implemented computer neural networks to analyze and classify it. Also, the actual mechanics of smelling something impacts the way the smell is received and processed in the brain. Computers and scientific instruments come in handy there as well. To really get to the core of human response to an aroma, lots of non-human tools are needed, and this is essentially where the TruffleBot fits in the greater realm of “olfactory” science.
I think this is a Sumerian variant for “fruity”. | Credit: AstroJane’s bathroom collection.
More Than Just Your Money
Perhaps one of the most innovative uses found for electronic noses is in disease research. One of the limitations of human smell is its overall weakness. A dog’s sense of smell is around 40 times better than a human’s, and a bear’s is a whopping 2,100 times superior to ours. That said, when researchers learned that certain diseases give off certain odors, the human nose wasn’t exactly the first choice to utilize in sensing them.
An electronic nose makes good use of the simple fact that organic matter releases chemicals into the air. For example, when a plant has been impacted by a fungus, the changes brought on in the plant’s structure release what’s called “volatile organic compounds” (VOCs). These VOCs can be detected by the sensors in an electronic nose and then provide information on the type of disease present without destroying the plants being tested.
Humans have some amazing things to gain from electronic noses, too. Using sensors to process odors from VOCs, things like digestive diseases, kidney diseases, and diabetes, among many others, are all receiving scientific attention for non-invasive diagnosis by these types of devices. With improvements brought on by inventions like TruffleBot, especially combined with its low-cost and resulting accessibility, a future involving remote diagnoses for any number of illnesses and diseases seems more possible every day.
Tesla stock (NASDAQ: TSLA) endured one of its sharpest single-day declines in years on July 23, tumbling approximately 14.5 percent and closing near $320 after opening the session around $374. The drop erased more than $140 billion in market value amid heavy trading volume and left the shares at multi-week lows.
The sell-off followed the company’s second-quarter 2026 results, released the previous evening. Tesla reported record revenue of $28.2 billion, up 26 percent year over year, driven by a Q2-record 480,126 vehicle deliveries. Energy storage deployments also rose strongly.
Tesla (TSLA) Q2 2026 earnings results: miss on EPS, beat on revenue
Yet profitability disappointed sharply. Operating income fell 57 percent to $398 million, compressing the operating margin to just 1.4 percent. Non-GAAP earnings per share came in at $0.33, well below the roughly $0.53 analysts had expected. Free cash flow turned negative by $1.1 billion as capital expenditures surged 142 percent to $5.8 billion, largely tied to accelerated spending on artificial intelligence, robotics, and autonomous systems.
The losses on capex were expected, as Tesla said it would be spending heavily in 2026.
Investors also reacted to lingering uncertainty surrounding key product timelines. During the Earnings Call, management reiterated ambitions for Robotaxi deployment and the Optimus humanoid robot, but offered limited new concrete milestones, renewing questions about execution pace that have long accompanied Tesla’s ambitious roadmap.
The magnitude of the decline places it among Tesla’s more severe one-day percentage losses since its 2010 initial public offering. Historically, the two largest single-day drops (split-adjusted) remain September 8, 2020, when shares fell 21.1 percent amid broader market volatility and valuation concerns, and January 13, 2012, with a 19.3 percent plunge during the company’s early growth struggles.
Other notable declines include an 18.6 percent drop on March 16, 2020, at the onset of pandemic-related market turmoil. Thursday’s move ranks roughly ninth on the all-time list but stands out as the steepest in more than a year.
Despite the short-term pain, Tesla’s long-term trajectory has repeatedly recovered from such volatility. The latest results underscore both the strength of its core automotive and energy businesses and the near-term costs of heavy investment in next-generation technologies.
Elon Musk clapped back at France’s decision to withhold the approval for Tesla’s Full Self-Driving (FSD) Supervised system, projecting a clear and blunt message to French Transport Minister Phillippe Tabarot, after he publicly rejected the technology in its current form.
Tabarot outlines several concerns with Tesla Full Self-Driving in a detailed video statement, where he said, “The safety trade-offs are not yet sufficient to authorize it as it currently stands,” he said. He emphasized that FSD is not a true self-driving system and that the driver remains fully responsible.
Key issues Tabarot also brought up included allowing speeding when surrounding traffic exceeds limits and what he believes are insufficient guarantees of driver attention during complex urban maneuvers such as lane changes, intersections, and roundabouts.
Delaying the approval of FSD in France will cost lives
— Elon Musk (@elonmusk) July 22, 2026
While acknowledging technological progress and France’s support for autonomous innovation, Tabarot stressed that deployment must prioritize road safety. He noted ongoing technical discussions with Tesla, the Netherlands, and other European partners, with further ecosystem meetings planned for the fall.
Musk’s rebuke highlights the human cost of regulatory caution. Tesla’s latest safety reports provide compelling data supporting accelerated adoption. In the most recent 12-month period, vehicles using FSD (Supervised) recorded one major collision per approximately 5.1 million miles driven, dramatically better than the U.S. national average of one crash per 698,000 miles.
Even Tesla vehicles driven manually with active safety features outperform the average by a wide margin. These figures come from billions of real-world miles of telemetry, showing FSD vehicles involved in far fewer incidents than both manual Teslas and the broader U.S. fleet.
Critics argue Tesla’s comparisons require careful scrutiny regarding reporting thresholds and fleet demographics, yet the data consistently positions FSD as a potential lifesaver. With road fatalities remaining a leading cause of death worldwide, Musk contends that proven safer technology should not face prolonged bureaucratic hurdles.
France’s measured approach reflects the broader European regulatory caution, which many, especially Musk, have been critical of in the past. However, as autonomous systems from Tesla and competitors like Waymo demonstrate superior safety in independent studies, pressure is mounting for harmonized approvals.
Musk’s warning carries the belief that every month of delay may equate to avoidable tragedies on European roads.
In a striking revelation that underscores the lucrative crossover between Big Tech and space exploration, Alphabet Inc., Google’s parent company, disclosed a massive $94.1 billion equity stake in SpaceX following the rocket company’s blockbuster initial public offering earlier this year.
The disclosure came in Alphabet’s quarterly filing, marking the first time the long-held private investment has been publicly valued at market prices. Google was an early backer, investing alongside Fidelity in 2015 with roughly $500-900 million at a time when SpaceX was valued around $12 billion.
That bet has delivered extraordinary returns, roughly a hundredfold, transforming a strategic play on satellite internet and launch capabilities into one of Alphabet’s largest assets.
Google, $GOOGL, has said they hold $94 billion in SpaceX, $SPCX, shares after IPO.
— unusual_whales (@unusual_whales) July 23, 2026
Of the total holding, approximately $80 billion remains subject to short-term post-IPO lockup restrictions, preventing near-term sales. An additional $14.1 billion faces longer-term restrictions, extending into the third quarter of 2027. This structure limits immediate liquidity but protects against market volatility as SpaceX transitions into public trading.
The SpaceX position contributed significantly to gains in Alphabet’s broader investment portfolio, which also includes a major stake in AI leader Anthropic. Combined, these holdings helped drive nearly $100 billion in investment gains during the second quarter, providing a substantial boost to net income amid ongoing AI spending pressures.
Analysts view the disclosure as validation of Alphabet’s venture strategy beyond its core search and cloud businesses. The investment aligns with deeper ties, including reported multi-billion-dollar deals for AI computing capacity on SpaceX infrastructure. As SpaceX advances Starship flights, Starlink expansion, and ambitious Mars goals under Elon Musk, Google’s stake positions it to benefit from the commercialization of space.
For Alphabet, the windfall highlights how patient, forward-looking bets in transformative sectors can yield outsized rewards. While lockups temper short-term impact, the holding cements SpaceX as a cornerstone of Alphabet’s diversified portfolio in an era where aerospace, AI, and connectivity increasingly intersect. Investors will watch closely as restrictions lift and SpaceX’s public performance unfolds.
Tesla stock tumbles after earnings, one of its sharpest single-day declines
Elon Musk is not happy about this Tesla Full Self-Driving approval delay
